In cardiac hypertrophy, the drug that participated in most of the dysregulated MGDTs was ATL1101, which is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor (IGF1R), a protein involved in the regulation of cell overgrowth in psoriasis. The gene discussed is IGF1R; the disease is cardiac hypertrophy.